ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2022
Differences of the Nasal Microbiome and Mycobiome by Clinical Characteristics of COPD Patients.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- The airway mycobiome in chronic respiratory diseases: current advances and future frontiers.Journal of translational medicine · 2025Review
- 16S rRNA sequencing-based analysis of sputum microbiome in patients with acute exacerbations of chronic obstructive pulmonary disease: retrospective cohort study.Journal of thoracic disease · 2025Article
- Nasopharyngeal microbiota is influenced by agricultural air pollution in individuals with and without COPD.Scientific reports · 2025Article
- Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.Open biology · 2025Review
- Integrated large-scale metagenome assembly and multi-kingdom network analyses identify sex differences in the human nasal microbiome.Genome biology · 2024Article
- Article
- Nasal biomarkers of immune function differ based on smoking and respiratory disease status.Physiological reports · 2023Article
- Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination.Analytical chemistry · 2022Article
- Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS-CoV-2 With ACE2-Inhibiting Activity Following mRNA Vaccination.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Rationale: While studies suggest that the lung microbiome may influence risk of chronic obstructive pulmonary disease (COPD) exacerbations, little is known about the relationship between the nasal biome and clinical characteristics of COPD patients. Methods: We sampled the nasal lining fluid by nasosorption of both nares of 20 people with moderate-to-severe COPD. All 40 samples, plus 4 negative controls, underwent DNA extraction, and 16SV4 ribosomal RNA (rRNA) (bacterial) and ribosomal internal transcribed spacer 2 (ITS2) (fungal) sequencing. We measured the proportion of variance (R Results: The most abundant nasal fluid bacterial taxa were Conclusion: The taxonomical composition of the nasal biome is heterogeneous in COPD patients and may be explained in part by clinical characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.